Polycystic Ovary Syndrome (PCOS) Treatment Market, By Drug Class (Oral contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors & SERMs and Diuretics), By Distribution Channel (Hospital Pharmac

Polycystic Ovary Syndrome (PCOS) Treatment Market, By Drug Class (Oral contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors & SERMs and Diuretics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Polycystic Ovarian Syndrome (PCOS) can be described as small sacs filled with fluid develop on the ovaries as a result of the endocrine system condition. Women with PCOS who are of childbearing age are affected. PCOS-positive women are more likely to experience miscarriage, gestational diabetes, pregnancy-induced hypertension, preeclampsia, and early birth. Moreover, women with PCOS may experience irregular menstrual cycles, elevated androgen (sex hormone) levels, excessive hair growth, acne, and obesity.

Women who have PCOS are more likely to develop serious health issues. These include type 2 diabetes, high blood pressure, heart and blood vessel problems, and uterine cancer. Women suffering from PCOS frequently struggle to conceive (fertility).

Market Dynamics

Effective use of oral contraceptives and increasing product value can drive the polycystic ovary syndrome (PCOS) treatment market over the forecast period. For instance, in August 2022, an article was published in the NCBI, according to which, for the treatment of PCOS, the major mechanism of action of oral contraceptives (OCs) is to control menstruation. These drugs also reduce hirsutism and acne by lowering testosterone levels. Thus, oral contraceptives are primary treatment for the polycystic ovary syndrome.

Moreover, rising awareness about novel mechanisms in the treatment of Polycystic Ovary Syndrome (PCOS) is anticipated to boost the growth of the market over the forecast period. For instance, according to research study published by Department of Obstetrics and Gynecology, China in November 2020, stated that the electroacupuncture (EA) intervention alleviated PCOS-like symptoms in rats by improving IR, mitochondrial dysfunction and oxidative stress through regulation of SREBP1, a regulator of lipid metabolism. The study findings illuminate the novel protective mechanisms of EA in the treatment of PCOS.

Key features of the study:

• This report provides in-depth analysis of the global Polycystic Ovary Syndrome (PCOS) Treatment market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Global Polycystic Ovary Syndrome (PCOS) Treatment Market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study Key companies covered as a part of this study Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Evotec SE, Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical and Sun Pharmaceutical Industries Ltd., Bayer AG, and other prominent players Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Polycystic Ovary Syndrome (PCOS) Treatment Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Polycystic Ovary Syndrome (PCOS) Treatment Market

Detailed Segmentation:

• Global Polycystic Ovary Syndrome (PCOS) Treatment Market, By Drug Class:
• Oral contraceptives
• Insulin Sensitizing Agents
• Anti-Depressants
• Ornithine Decarboxylase Inhibitors
• Aromatase Inhibitors & SERMs
• Diuretics
• Global Polycystic Ovary Syndrome (PCOS) Treatment Market By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Polycystic Ovary Syndrome (PCOS) Treatment Market, By Region:
• North America
• By Country:
• U.S.
• Canada
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country:
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region:
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Sanofi S.A.*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Amneal Pharmaceuticals, Inc.
• Laurus Labs Limited
• Zydus Pharmaceuticals, Inc.
• Prasco Laboratories
• Reddy's Laboratories
• Cadila Pharmaceuticals
• Novartis International AG
• Concordia Pharmaceuticals Inc.
• Covis Pharmaceuticals, Inc.
• Cardinal Health
• Aphena Pharma Solutions Tennessee, Inc.
• Mylan N.V.
• McKesson Corporation
• Teva Pharmaceutical Industries Ltd
• Lupin Pharmaceutical
• Sun Pharmaceutical Industries Ltd.

“*” marked represents similar segmentation in other categories in the respective section.